Cogent Biosciences(COGT)
WALTHAM, MA
Biotechnology1 H-1B visas (FY2023)Focus: Cellular immunotherapies
Cogent Biosciences is a life sciences company focused on Cellular immunotherapies.
OncologyNeurology
Funding Stage
PUBLIC
Open Jobs
53
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT06948955Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
N/AACTR T Cell Product
B Cell LymphomasClinical Trials (1)
NCT02840110Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
N/ABezuclastinib
Systemic Mastocytoses, IndolentClinical Trials (1)
NCT06915766Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
N/AREBUILD Bioabsorbable
LaparotomyClinical Trials (1)
NCT05041530Abdominal Wall Closure After Laparotomy in Oncologic Surgery
N/AREBUILD
Surgical IncisionClinical Trials (1)
NCT05687942The REBUILD Trial: Closure of the Abdominal Wall
N/AACTR707
LymphomaClinical Trials (1)
NCT03189836Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Phase 1CGT4255
Advanced Solid Tumor, AdultClinical Trials (1)
NCT07361562A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1ACTR T Cell Product
Solid TumorClinical Trials (1)
NCT03680560Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Phase 1ACTR087
Multiple MyelomaClinical Trials (1)
NCT03266692Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1CGT6297
PIK3CA MutationsClinical Trials (1)
NCT07383506A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Phase 1ACTR087
LymphomaClinical Trials (1)
NCT02776813Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Phase 1Phase 1/2
Clinical Trials (1)
NCT02401815CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Phase 1/2Phase 1/2
Clinical Trials (1)
NCT06777316A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Phase 1/2bezuclastinib
Advanced Systemic Mastocytosis (AdvSM)Clinical Trials (1)
NCT04996875(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Phase 2Bezuclastinib Tablets
SSMClinical Trials (1)
NCT05186753(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Phase 2Bezuclastinib in combination with sunitinib
Gastrointestinal Stromal TumorsClinical Trials (1)
NCT06208748SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
Phase 2CGT9486 plus sunitinib
Advanced Gastrointestinal Stromal TumorsClinical Trials (1)
NCT05208047(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Phase 3Open Jobs (53)
Director, National Accounts
Waltham, Massachusetts, United States
Development5d ago
$220K - $260K/yr
Clinical Account Manager - Chicago S, IL
Chicago S, IL
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Denver, CO
Denver, CO
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Las Vegas, NV
Las Vegas, NV
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - San Diego, CA
San Diego, CA
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Los Angeles, CA
Los Angeles, CA
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - San Francisco, CA
San Francisco, CA
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Sacramento, CA
Sacramento, CA
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Mountain States, ID
Salt Lake City, UT
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Seattle, WA
Seattle, WA
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Kansas City, KS
Kansas City, KS
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Houston, TX
Houston, TX
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Dallas, TX
Dallas, TX
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - San Antonio, TX
San Antonio, TX
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Phoenix, AZ
Phoenix, AZ
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Arkansas
Arkansas
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Central Plains
Des Moines, IA
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - St. Louis, MO
St. Louis, MO
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Indianapolis, IN
Indianapolis, IN
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Chicago N, IL
Chicago N, IL
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Detroit, MI
Detroit, MI
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Minneapolis, MN
Minneapolis, MN
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Miami, FL
Miami, FL
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Tampa, FL
Tampa, FL
Commercial1w ago
$200K - $240K/yr
Clinical Account Manager - Orlando, FL
Orlando, FL
Commercial1w ago
$200K - $240K/yr
Interview Prep Quick Facts
Founded: 2007
Portfolio: 17 clinical trials
Top TAs: Oncology
H-1B (2023): 1 approval
SEC Filings: 2 available
Open Roles: 53 active jobs
Hiring Trend
Stable
53
Open Roles
+1
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub